HCA Healthcare
HCA Healthcare's revenue rose 7.1% to $75.6 billion in fiscal 2025. Its net margin was 9.0%, up from 8.2% a year earlier. Free cash flow was $7.7 billion, up 36.4%. It paid out $10.7 billion in dividends and buybacks, 140% of free cash flow. The diluted share count fell 8.5%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What HCA Healthcare does
HCA Healthcare runs hospitals and other health care facilities in 19 U.S. states and England. At the end of 2025 it operated 190 hospitals: 179 general acute care hospitals, seven behavioral hospitals and four rehabilitation hospitals. It also ran 121 freestanding ambulatory surgery centers and 31 freestanding endoscopy centers.
Its general hospitals provide medical services such as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, plus diagnostic and emergency care. It also provides outpatient care through surgery centers, emergency and urgent care facilities, walk-in clinics, physician practices, diagnostic centers, home health agencies, hospices and rehabilitation facilities. The behavioral hospitals provide mental health care.
HCA earns its money by charging for care, paid for by government programs, private insurers and patients. Its 10-K ties its results to changes in government health care programs, to keeping patients with private insurance, and to the number of uninsured patients. It began operating through its predecessors in 1968 and is based in Nashville, Tennessee.
Its biggest risks, as it describes them
- Significant debt, and the need to generate cash to pay it or refinance it.
- Competition for nurses, physicians and other health care workers, and a shortage of experienced staff.
- Changes in government health care programs that could cut its revenue.
- Government investigations, claims and lawsuits over billing and compliance with laws such as the Anti-kickback Statute.
- More uninsured patients, or a drop in patients with private insurance.
Income statement
From fiscal 2016 to 2025, earnings per share grew 16.3% a year and net income 9.9% a year, as buybacks cut the share count by 40%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1.6 | 0.9 | 0.9 | 1.9 | 1.0 |
| Debt incl. finance leases | 35.3 | 38.8 | 40.3 | 43.8 | 47.2 |
| Net debt (negative means net cash) | 33.7 | 37.9 | 39.4 | 41.9 | 46.2 |
| Net debt to EBITDA | 2.4x | 2.9x | 3.1x | 3.0x | 3.0x |
| Debt to equity | — | — | — | — | — |
| Interest coverage | 7.3x | 5.9x | 5.0x | 5.1x | 5.4x |
| Current ratio | 1.4x | 1.4x | 1.2x | 1.1x | 1.0x |
| Quick ratio | 1.2x | 1.2x | 1.0x | 1.0x | 0.9x |
Cash flow
Projections
Project HCA Healthcare's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought HCA Healthcare shares on the open market, and 8 insiders sold $47.5 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 10, 2026 | Erica RossittoSVP & Chief Nurse Executive | Sold | 3,500 | $505.81 | $1.8 million | Form 4 |
| Nov 6, 2026 | Jon M FosterEVP and COO | Sold | 21,713 | $494.95 | $10.7 million | Form 4 |
| Nov 4, 2026 | Jon M FosterEVP and COO | Sold | 10,000 | $514.07 | $5.1 million | Form 4 |
| Nov 4, 2026 | Michael J SchlosserEVP and Chief Clinical Officer | Sold | 1,200 | $494.65 | $593,583 | Form 4 |
| Feb 18, 2026 | Michael R McAleveyEVP & Chief Legal & Admin Off. | Sold | 1,694 | $533.37 | $903,529 | Form 4 |
| Feb 11, 2026 | Jennifer BerresSVP & Chief Human Res. Officer | Sold | 8,020 | $514.58 | $4.1 million | Form 4 |
| Feb 11, 2026 | Christopher F. WyattSVP & Controller | Sold | 4,000 | $505.00 | $2.0 million | Form 4 |
| Feb 3, 2026 | Samuel N HazenCEO, Director | Sold | 42,877 | $501.04 | $21.5 million | Form 4 |
| Feb 3, 2026 | Michael S. CuffeEVP and Chief Clinical Officer | Sold | 1,500 | $498.09 | $747,135 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 6 of 8 | 6 of 8 | 6 of 8 |
| Rule of 40 | 15.1% | 16.7% | 17.2% |
| Altman Z'' | 1.36 | 1.23 | 0.92 |
| Accruals ratio | −7.7% | −8.2% | −9.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Pass | Pass | Pass |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 6 of 8 | 6 of 8 | 6 of 8 |
Compare
Put HCA Healthcare side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| HCA Healthcare | FY25 | 7.1% | — | 10.2% | 22.3% | 3.0x | 6 | |
| UnitedHealth | FY25 | 11.8% | 4.2% | 3.6% | 11.2% | 2.2x | 7 | Compare |
| Johnson & Johnson | FY25 | 6.0% | — | 20.9% | 28.6% | 0.7x | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 41.5 | 43.6 | 46.7 | 51.3 | 51.5 | 58.8 | 60.2 | 65.0 | 70.6 | 75.6 |
| Revenue growth | — | 5.1% | 7.0% | 10.0% | 0.4% | 14.0% | 2.5% | 7.9% | 8.7% | 7.1% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — | — | — |
| Net income | 2.9 | 2.2 | 3.8 | 3.5 | 3.8 | 7.0 | 5.6 | 5.2 | 5.8 | 6.8 |
| Diluted EPS (US$) | 7.30 | 5.95 | 10.66 | 10.07 | 10.93 | 21.16 | 19.15 | 18.97 | 22.00 | 28.33 |
| Diluted shares (millions) | 396 | 372 | 355 | 348 | 344 | 329 | 295 | 276 | 262 | 240 |
| Cash flow | ||||||||||
| Cash from operations | 5.7 | 5.4 | 6.8 | 7.6 | 9.2 | 9.0 | 8.5 | 9.4 | 10.5 | 12.6 |
| Capital expenditure | 2.8 | 3.0 | 3.6 | 4.2 | 2.8 | 3.6 | 4.4 | 4.7 | 4.9 | 4.9 |
| Free cash flow | 2.9 | 2.4 | 3.2 | 3.4 | 6.4 | 5.4 | 4.1 | 4.7 | 5.6 | 7.7 |
| Dividends paid | 0.0 | 0.0 | 0.5 | 0.6 | 0.2 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 |
| Share buybacks | 2.8 | 2.1 | 1.5 | 1.0 | 0.4 | 8.2 | 7.0 | 3.8 | 6.0 | 10.1 |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Stock-based compensation | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 0.6 | 0.7 | 0.5 | 0.6 | 1.9 | 1.6 | 0.9 | 0.9 | 1.9 | 1.0 |
| Debt incl. finance leases | 31.4 | 33.1 | 32.8 | 34.3 | 31.6 | 35.3 | 38.8 | 40.3 | 43.8 | 47.2 |
| Total assets | 33.8 | 36.6 | 39.2 | 45.1 | 47.5 | 50.7 | 52.4 | 56.2 | 59.5 | 60.7 |
| Total liabilities | 39.4 | 41.6 | 42.1 | 45.6 | 44.6 | 49.3 | 52.5 | 55.2 | 59.0 | 63.5 |
| Shareholders' equity | −7.3 | −6.8 | −5.0 | −2.8 | 0.6 | −0.9 | −2.8 | −1.8 | −2.5 | −6.0 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Net margin | 7.0% | 5.1% | 8.1% | 6.8% | 7.3% | 11.8% | 9.4% | 8.1% | 8.2% | 9.0% |
| Free cash flow margin | 7.0% | 5.5% | 6.8% | 6.7% | 12.4% | 9.2% | 6.8% | 7.2% | 8.0% | 10.2% |
| Rule of 40 (growth + FCF margin) | — | 10.7% | 13.8% | 16.7% | 12.8% | 23.2% | 9.4% | 15.1% | 16.7% | 17.2% |
| Return on capital | 19.1% | 14.5% | 20.6% | 17.9% | 17.2% | 26.4% | 22.5% | 19.5% | 19.9% | 22.3% |
| Return on equity | — | — | — | — | — | — | — | — | — | — |
| Return on assets | 8.7% | 6.3% | 10.0% | 8.3% | 8.1% | 14.2% | 10.9% | 9.7% | 9.9% | 11.3% |
| Net debt to EBITDA | 3.6x | 3.9x | 3.5x | 3.5x | 3.0x | 2.4x | 2.9x | 3.1x | 3.0x | 3.0x |